Background/Aims Acute liver failure (ALF) has high mortality predominantly due to compromised immune system and increased vulnerability to bacterial and fungal infections.
Methods Plasma lipidome and fungal peptide-based community (mycobiome) analysis were performed in discovery cohort (ALF=40, healthy=5) and validated in a validation cohort of 230 patients with ALF using high-resolution-mass-spectrometry, artificial neural network (ANN) and machine learning (ML).
Results Untargeted lipidomics identified 2,013 lipids across 8 lipid group. 5 lipid-species—phosphatidylcholine (PC)[15:0/17:0], PC[20:1/14:1], PC[26:4/10:0], PC[32:0] and TG[4:0/10:0/23:6]—significantly differentiated ALF-NS (FC>10, P<0.05, FDR<0.01). Mycobiome alpha/beta diversity was significantly higher and showed 4 phyla and >20 species significantly dysregulated in ALF-NS linked with lipid metabolism, fatty acid elongation in ER, and others (P<0.05). Lipid and mycobiome diversity values in ALF-NS were strongly correlated (r2>0.7, P<0.05). Multi-modular correlation network showed striking associations between lipid, fungal peptide modules, and clinical parameters specific to ALF-NS (P<0.05). Cryptococcus amylolentus CBS6039 and Penicillium oxalicum 1142 directly correlated with phosphatidylcholine, triglycerides, and severity in ALF-NS (r2>0.85, P<0.05). POD-fungus and POD-lipids showed direct association with infection, necrosis, and hepatic encephalopathy (Beta>1.2, P<0.05). POD-lipid (AUC=0.969 and HR=1.99 [1.02–2.04]) superseded POD-fungus and severity indices for early-mortality prediction. Finally, significant increase in PC (15:0/17:0) level showed highest normalized importance, and ANNs and ML predicted early mortality with >95% accuracy, sensitivity, and specificity. Interestingly, fungal surveillance protein Clec7a was significantly downregulated (>2-fold), leading to a notable increase in fungal infection-mediated choline/phosphatidylcholine and associated enzymes (FC>1.5; Kennedy cycle). This contributed to phosphatidic acid-mediated hyper-inflammation in ALF-NS.
Conclusions In ALF, the plasma lipidome and mycobiome are dysregulated. Increased circulating phosphatidylcholine could stratify ALF predisposed to early mortality or require emergency liver transplantation.
9,438
View
260
Download
Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)
Severe alcoholic hepatitis (SAH) remains a disease with high mortality. Steroid is the main stay and has been shown to give modest 28-day survival benefit in carefully selected patients, but no 90-day survival benefit. Since non-responders have high incidence of infections and increased mortality, it would be worthwhile to identify them before starting steroid therapy. A high and rising bilirubin, urinary acetyl carnitine >2,500 ng/mL, high asiloglycoprotein positive microparticles, and specific features in liver biopsy could predict steroid non-response at baseline. There is an ever-growing need to find new and effective therapies for SAH patients. Besides aggressive nutrition, granulocyte colony stimulating factor, fecal microbiota transplantation, and plasma exchange appear promising therapies and provide a hope for steroid ineligible or steroid non-responsive patients. Suppression of hepatic inflammation, preventing new bacterial or fungal infections, and enhancing liver regeneration will remain the key targets for next generation therapies.
Citations
Citations to this article as recorded by
Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space–time coordinates as prognostic tool and therapeutic target Ľubomír Skladaný, Daniela Žilinčanová, Natália Kubánek, Svetlana Adamcová Selčanová, Daniel Havaj, Lukáš Laffers, Michal Žilinčan, Alvi H Islam, Juan Pablo Arab, Tomáš Koller Alcohol and Alcoholism.2025;[Epub] CrossRef
New Approaches to Alcohol-Associated Hepatitis Rohit Sunilrao Wagh, Saggere Muralikrishna Shasthry, Shiv Kumar Sarin Clinics in Liver Disease.2025; 29(4): 595. CrossRef
Patient factors in responders and non-responders treated with steroids for acute alcohol-associated hepatitis Kent W Sabatose, Alexandra Baker, Kevin Kugler, Jude Delikat, Bethany Jowers, Ambuj Kumar, Sadaf Aslam, Jacentha Buggs, Christine Machado-Denis, Nyingi Kemmer, Kiran Dhanireddy, Rashid Syed World Journal of Hepatology.2025;[Epub] CrossRef
Predicting steroid response in acute alcohol-associated hepatitis: Beyond biomarkers of alcohol consumption Jin-Wei Zhang World Journal of Hepatology.2025;[Epub] CrossRef
Severity of Acute Portal Hypertension Determines the Clinical Outcomes in Severe Alcoholic Hepatitis Ankur Jindal, Manoj K. Sharma, Rajan Vijayaraghavan, Shasthry SM, Guresh Kumar, Shiv K. Sarin Digestive Diseases and Sciences.2024; 69(1): 298. CrossRef
Real-World Utilization of Corticosteroids in Severe Alcoholic Hepatitis: Eligibility, Response, and Outcomes Ana-Maria Singeap, Horia Minea, Oana Petrea, Madalina-Andreea Robea, Ioana-Miruna Balmuș, Raluca Duta, Ovidiu-Dumitru Ilie, Carmen Diana Cimpoesu, Carol Stanciu, Anca Trifan Medicina.2024; 60(2): 311. CrossRef
Utility of Lille Score in Predicting 30-Day Survival in Steroid-Treated Alcohol-Associated Hepatitis Marcus A. Healey, Geetha Ramalingam, Yiwei Hang, Ekaterina Smirnova, Amon Asgharpour, Vaishali Patel, Hannah Lee, Velimir Luketic, Scott Matherly, Mohammad Siddiqui, Joel Wedd, Arun Sanyal, Richard K. Sterling Digestive Diseases and Sciences.2024; 69(8): 3043. CrossRef
Quercetin alleviates ethanol‐induced hepatic steatosis in L02 cells by activating TFEB translocation to compensate for inadequate autophagy Xingtao Zhao, Xinyan Xue, Jing Wang, Shu Dai, Cheng Peng, Yunxia Li Phytotherapy Research.2023; 37(1): 62. CrossRef
Patients with a History of Bariatric Surgery Are 8 Years Younger at Presentation with Severe Alcoholic Hepatitis Lukas Van Melkebeke, Annelotte G. C. Broekhoven, Tessa Ostyn, Hannelie Korf, Minneke J. Coenraad, Roman Vangoitsenhoven, Bart Van der Schueren, Matthias Lannoo, Hannah Van Malenstein, Tania Roskams, Schalk van der Merwe, Frederik Nevens, Jef Verbeek Obesity Surgery.2023; 33(1): 284. CrossRef
AARC score determines outcomes in patients with alcohol-associated hepatitis: a multinational study Rakhi Maiwall, Samba Siva Rao Pasupuleti, Ashok Choudhury, Dong Joon kim, Ajit Sood, Omesh Goyal, Vandana Midha, Harshad Devarbhavi, Anil Arora, Ashish Kumar, Manoj Kumar Sahu, Sudhir Maharshi, Ajay Kumar Duseja, Virendra Singh, Sunil Taneja, P. N. Rao, A Hepatology International.2023; 17(3): 662. CrossRef
Management of alcoholic hepatitis: A clinical perspective Philipp Kasper, Sonja Lang, Hans‐Michael Steffen, Münevver Demir Liver International.2023; 43(10): 2078. CrossRef
Efficiency of glucocorticosteroids in severe alcoholic hepatitis A. S. Rodina, I. V. Kurbatova, M. E. Shubina, O. P. Dudanova Meditsinskiy sovet = Medical Council.2023; (8): 135. CrossRef
Past, Present, and Future Therapies for Alcohol-associated Hepatitis Sally Condon, Loretta L. Jophlin Clinical Therapeutics.2023; 45(12): 1171. CrossRef
Mesenchymal stem cells-based therapy in liver diseases Heng-Tong Han, Wei-Lin Jin, Xun Li Molecular Biomedicine.2022;[Epub] CrossRef
Can granulocyte colony stimulating factor (G-CSF) ameliorate acetaminophen-induced hepatotoxicity? EA Ahmed, AM Abd-Eldayem, E Ahmed Human & Experimental Toxicology.2021; 40(10): 1755. CrossRef
Treatment of severe alcoholic hepatitis: A systematic review Lukas Van Melkebeke, Hannelie Korf, Emmanuel A. Tsochatzis, Schalk van der Merwe, Frederik Nevens, Jef Verbeek Current Opinion in Pharmacology.2021; 60: 91. CrossRef
First
Prev
